search button
Open Access

miR‑29b‑3p inhibits 22Rv1 prostate cancer cell proliferation through the YWHAE/BCL‑2 regulatory axis

  • Authors:
    • Jiafu Zhao
    • Xiaoyan Ma
    • Houqiang Xu

  • View Affiliations

  • Published online on: July 1, 2022     https://doi.org/10.3892/ol.2022.13409
  • Article Number: 289

  • Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Prostate cancer (PCa) is one of the most common malignant tumours in the world and seriously affects health of men. Studies have shown that microRNA (miR)‑29b‑3p and tyrosine 3‑monooxygenase/tryptophan 5‑monooxygenase activation protein epsilon (YWHAE) play important roles in influencing the proliferation and apoptosis of PCa cells. However, the molecular mechanism of miR‑29b‑3p and YWHAE in the proliferation and apoptosis of PCa cells remains unclear. In the present study, bioinformatics as well as in vivo and in vitro experiments were used to predict and verify the targeting relationship between YWHAE and mir‑29B‑3p and investigate the potential roles of YWHAE and mir‑29b‑3p in the proliferation and apoptosis of 22RV1 cells. Using bioinformatics and a double luciferase system assay, it was confirmed that miR‑29b‑3p can target YWHAE 3'untranslated region and affect the expression of YWHAE, suggesting that miR‑29b‑3p may be a potential miRNA of YWHAE. Reverse transcription‑quantitative PCR, Cell Counting Kit‑8, Transwell and cell scratch assays showed that miR‑29b‑3p significantly inhibited the proliferation, invasion and migration of 22Rv1 cells (P<0.01). Rescue experiments demonstrated that YWHAE gene introduction reversed the inhibitory effect of miR‑29b‑3p on 22Rv1 cells. Western blotting revealed that the upregulation of miR‑29b‑3p inhibited YWHAE expression, resulting in a very significant decrease in the ratio of p‑BAD/BAD and full‑length caspase 3/cleaved caspase 3 (P<0.01) and an extremely significant increase in the ratio of BAX/BCL‑2 (P<0.01). A tumourigenesis test in nude mice in vivo confirmed that the upregulation of miR‑29b‑3p inhibited tumour growth by targeting YWHAE. The present experiments confirmed that miR‑29b‑3p plays a tumour suppressor role in 22Rv1 PCa cells, and the YWHAE/BCL‑2 regulatory axis plays a vital role in miR‑29b‑3p regulating the proliferation and apoptosis of 22Rv1 cells. These results may provide a theoretical basis for the diagnosis and targeted treatment of PCa.
View Figures
View References

Related Articles

Journal Cover

August-2022
Volume 24 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Zhao J, Ma X and Xu H: miR‑29b‑3p inhibits 22Rv1 prostate cancer cell proliferation through the YWHAE/BCL‑2 regulatory axis. Oncol Lett 24: 289, 2022
APA
Zhao, J., Ma, X., & Xu, H. (2022). miR‑29b‑3p inhibits 22Rv1 prostate cancer cell proliferation through the YWHAE/BCL‑2 regulatory axis. Oncology Letters, 24, 289. https://doi.org/10.3892/ol.2022.13409
MLA
Zhao, J., Ma, X., Xu, H."miR‑29b‑3p inhibits 22Rv1 prostate cancer cell proliferation through the YWHAE/BCL‑2 regulatory axis". Oncology Letters 24.2 (2022): 289.
Chicago
Zhao, J., Ma, X., Xu, H."miR‑29b‑3p inhibits 22Rv1 prostate cancer cell proliferation through the YWHAE/BCL‑2 regulatory axis". Oncology Letters 24, no. 2 (2022): 289. https://doi.org/10.3892/ol.2022.13409